Re-Thinking Pharmaceutical Production in Africa; Insights from the Analysis of the Local Manufacturing Dynamics in Mozambique and Zimbabwe

Abstract

Until recently, consensus existed in certain circles that the African industry was not suitable for cost-effective production of quality, safe drugs. Yet, public and private pharmaceutical enterprises have cropped up on the continent, with some venturing into production of sophisticated and complex drugs, such as antiretrovirals (ARVs). In our study, we analyse and contrast the dynamics of local pharmaceutical manufacturing in Mozambique and Zimbabwe with the objective of understanding why pharmaceutical production in Africa is picking up momentum and the influence of global funding for ARVs in this process. Our analysis identifies two routes of development for local pharmaceutical manufacturing: a favourable economic outlook and support from the international community created the necessary conditions for the development of the nascent pharmaceutical industry in Mozambique, while in Zimbabwe, the presence of an established local industry was instrumental in bringing in favourable, if not always coherent, government regulation. In both countries, the introduction of AIDS treatment created windows of opportunity for local production of pharmaceuticals by increasing public sector demand, providing fresh funds, and providing a justification for government regulation favouring local production. Despite the long-standing and well-known problems that created persistent shortcomings in human resources and in the economic and industrial environments, we conclude that pre-existing developmental roots, international funds and supportive state industrial policies are encouraging more manufacturers to enter the business of local pharmaceutical production in Africa. However, the opportunities brought in by fresh AIDS funds St Comp Int Dev

Strategic sourcing in Africa: the case for the labor market

“…Many countries in Africa now offer a favorable business landscape despite social, economic and political challenges in some regions. As Russo and Banda (2015) noted, Mozambique and Zimbabwe enabled the expansion of private and public pharmaceutical enterprises, some of which ventured into the production of sophisticated and complex drugs despite the reluctance from the industry. The industrialization of African countries is no longer a matter of when, but rather a matter of where it appears.…”

How Do Experts Resist a Development Cooperation Project? The Case of the Mozambique-Brazil Generic Medicine Factory

“…The context of existing regional pharmaceutical units and the constraints already experienced by those plants also indicated the complexities of the task (Russo and Banda 2015). It was therefore not considered by experts to be a suitable candidate for the Brazilian offer to transfer technology of ARV production with the aim to increase the access of local populations to HIV/AIDS therapies.…”

“…To make that happen would require policies regarding intellectual property and patent of medicines, coordinated within the SADC countries on a regional level by the African Regional Intellectual Property Organization (ARIPO), which also lacked the critical capacity to harmonise and design relevant legislation to encourage local production of medicines (Avafia 2015). Other major policy changes had to be made, such as linking the industrial policy with public health objectives, including introducing fiscal incentives and subsidies, and ensuring the government and donors were engaged to buy the local production (Pinheiro et al 2014;Russo and Banda 2015).…”

La production locale de médicaments génériques au Mozambique à la croisée des circulations de savoirs pharmaceutiques

“…L'idéal du transfert horizontal des connaissances entre des professionnels issus de pays en développement, même à niveau de formation supérieure égale, ne résiste pas à l'asymétrie des compétences et d'expérience professionnelle dans l'industrie pharmaceutique (Esteves et Assunção, 2017). L'accumulation à long terme de cette formation pose problème, comme dans d'autres industries pharmaceutiques africaines, du fait de la difficulté de garder la maind'oeuvre formée, attirée par des offres d'emplois mieux rémunérés dans le privé ou auprès des ONG internationales (Russo et Banda, 2015). Aussi, si l'apprentissage technologique se concrétise par la pratique, l'absence de production en continu -la production de comprimés a été complètement interrompue d'avril 2016 à mars 2018 en raison de l'interruption des financements brésiliens et de la crise des dettes secrètes mozambicaines 10 -limite la maîtrise des savoir-faire par le personnel de l'usine.…”